A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants.

Authors :: Qing Zhu
McLellan, Jason S.
Kallewaard, Nicole L.
Ulbrandt, Nancy D.
Palaszynski, Susan
Jing Zhang
Moldt, Brian
Khan, Anis
Svabek, Catherine
McAuliffe, Josephine M.
Wrapp, Daniel
Patel, Nita K.
Cook, Kimberly E.
Richter, Bettina W. M.
Ryan, Patricia C.
Yuan, Andy Q.
Suzich, JoAnn A.
Source :: Science Translational Medicine; 5/3/2017, Vol. 9 Issue 388, p1-11, 11p
Publication Year :: 2017
Abstract: The article discusses the development of monoclonal antibody MEDI8897 as a potential respiratory syncytial virus (RSV) prophylaxis for all infants. It mentions that the prevention of RSV illness in all infants is considered as a major public health priority wherein palivizumab is the only approved agent for RSV prophylaxis. It notes that the pharmacokinetics of palivizumab in infants supports the development of MEDI8897 as a cost-effective option to protect all infants from RSV disease.

Subjects :: DRUG development
MONOCLONAL antibodies
VIRAL diseases in children
INFANT disease prevention
RESPIRATORY syncytial virus infections
THERAPEUTICS

Full Text Access

Tools